Hypertension — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypertension. 24 active patents protecting 3 drugs from 2+ originators. First major cliff: 2029. Daily refresh.

3
Approved drugs
24
Active US patents
56/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypertension

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 16 patents Idorsia 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypertension. Each bar = one year. Y-axis scaled to peak year (11 patents).

4
29
2
33
1
37
11
38
6
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Caduet
Amlodipine Besylate
 Pfizer Inc. 16 63 — 2029-10-05
Tryvio
APROCITENTAN
 Idorsia 6 63 — 2029-09-21
TORSEMIDE — 2 42 — 2033-10-06

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8324232 Tryvio method of use 81 2029-09-21
11174247 Tryvio method of use 75 2037-11-06
10799487 Caduet method of use 75 2038-01-23
11787782 Tryvio method of use 75 2038-03-02
11680058 Tryvio method of use 75 2038-07-26
12226528 Caduet method of use 75 2041-02-24
12005141 Caduet method of use 75 2041-02-24
12440441 Caduet method of use 75 2041-02-24
11253474 Caduet method of use 70 2041-02-24
11458095 Caduet method of use 70 2041-02-24

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10919881 Tryvio composition of matter 17 2038-02-26
10350171 Caduet formulation 42 2038-06-14
10350171 Caduet formulation 42 2038-06-14
10350171 Caduet formulation 42 2038-06-14
10154963 TORSEMIDE formulation 42 2033-10-06
10154963 TORSEMIDE formulation 42 2033-10-06
12297189 Tryvio formulation 55 2038-02-26
10322117 Caduet formulation 55 2038-01-23
12465599 Caduet formulation 55 2038-01-23
12465599 Caduet formulation 55 2038-01-23

Related